{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:18:41Z","timestamp":1772788721060,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.vaccine.2011.04.050","type":"journal-article","created":{"date-parts":[[2011,5,8]],"date-time":"2011-05-08T03:12:26Z","timestamp":1304824346000},"page":"4601-4607","source":"Crossref","is-referenced-by-count":24,"title":["Reported adverse events in girls aged 13\u201316 years after vaccination with the human papillomavirus (HPV)-16\/18 vaccine in the Netherlands"],"prefix":"10.1016","volume":"29","author":[{"given":"T.M. van\u2019t","family":"Klooster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Kemmeren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.A.T.","family":"van der Maas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.04.050_bib0005","series-title":"Vaccination against cervical cancer","author":"Dutch Health Council","year":"2008"},{"key":"10.1016\/j.vaccine.2011.04.050_bib0010","first-page":"A67","article-title":"Introduction of vaccination against cervical cancer","volume":"153","author":"de Melker","year":"2009","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"June (9580)","key":"10.1016\/j.vaccine.2011.04.050_bib0015","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2011.04.050_bib0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Health"},{"issue":"November (9447)","key":"10.1016\/j.vaccine.2011.04.050_bib0025","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2011.04.050_bib0030","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3346\/jkms.2010.25.8.1197","article-title":"Vaccination with a human papillomavirus (HPV)-16\/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10\u201314 years","volume":"25","author":"Kim","year":"2010","journal-title":"J Korean Med Sci"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2011.04.050_bib0035","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jadohealth.2010.02.006","article-title":"HPV-013 Study Group. Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls","volume":"46","author":"Medina","year":"2010","journal-title":"J Adolesc Health"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.04.050_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","article-title":"Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10\u201318 years","volume":"44","author":"Pet\u00e4j\u00e4","year":"2009","journal-title":"J Adolesc Health"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2011.04.050_bib0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"May (19)","key":"10.1016\/j.vaccine.2011.04.050_bib0050","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Females united to unilaterally reduce endo\/ectocervical disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"January (5\u20136)","key":"10.1016\/j.vaccine.2011.04.050_bib0055","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.vaccine.2003.09.007","article-title":"Brighton Collaboration Fever Working Group. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation","volume":"22","author":"Marcy","year":"2004","journal-title":"Vaccine"},{"issue":"December (3\u20134)","key":"10.1016\/j.vaccine.2011.04.050_bib0060","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(02)00449-8","article-title":"The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)","volume":"21","author":"Bonhoeffer","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.050_bib0065","doi-asserted-by":"crossref","unstructured":"Kemmeren JM, van der Maas NA, de Melker HE. Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children. Eur J Pediatr Epub 2010 September 21.","DOI":"10.1007\/s00431-010-1294-4"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2011.04.050_bib0070","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/INF.0b013e318162a127","article-title":"The effect of age and dose number on the risk of collapse (hypotonic-hyporesponsive episode) after pertussis vaccination","volume":"27","author":"Vermeer-de Bondt","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"June (19\u201320)","key":"10.1016\/j.vaccine.2011.04.050_bib0075","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/S0264-410X(03)00173-7","article-title":"Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine","volume":"21","author":"Halperin","year":"2003","journal-title":"Vaccine"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2011.04.050_bib0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5694\/j.1326-5377.2003.tb05497.x","article-title":"Local reactions after the fourth dose of acellular pertussis vaccine in South Australia","volume":"179","author":"Gold","year":"2003","journal-title":"Med J Aust"},{"issue":"March (13)","key":"10.1016\/j.vaccine.2011.04.050_bib0085","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.vaccine.2005.12.009","article-title":"Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review","volume":"24","author":"Jacquet","year":"2006","journal-title":"Vaccine"},{"issue":"A980","key":"10.1016\/j.vaccine.2011.04.050_bib0090","article-title":"Increase in localised symptoms in 4-year-olds following revaccination with DaPT-IPV","volume":"154","author":"David","year":"2010","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.vaccine.2011.04.050_bib0095","unstructured":"van\u2019t Klooster TM, Kemmeren JM, Vermeer-de Bondt PE, Oostvogels B, Phaff T, de Melker HE, et al. Human papillomavirus vaccination catch-up campaign in 2009 for girls born in 1993\u20131996 in the Netherlands: results of the post-marketing safety surveillance. Bilthoven; 2011. Report No.: 210012001."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11005950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11005950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:15:46Z","timestamp":1592525746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11005950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":19,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0264410X11005950"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.04.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}